News & Updates
Showing Multidisciplinary articles
Showing
GARNET updates confirm long-term dostarlimab benefit in dMMR/MSI-H endometrial cancer
Updates from the GARNET trial underpin dostarlimab monotherapy as a meaningful treatment option for women with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) advanced/recurrent endometrial cancer (A/R EC) who progressed after prior platinum therapy.
GARNET updates confirm long-term dostarlimab benefit in dMMR/MSI-H endometrial cancer
09 Jul 2026
Oral paclitaxel on par with IV formulation in HER2-negative breast cancer
A novel oral formulation of paclitaxel, DHP107, is noninferior to weekly intravenous (IV) paclitaxel in the treatment of HER2-negative recurrent or metastatic breast cancer, as shown by the results of the phase III OPTIMAL study.
Oral paclitaxel on par with IV formulation in HER2-negative breast cancer
08 Jul 2026
MonumenTAL-3 supports talquetamab–daratumumab ± pomalidomide for RRMM
In the phase III MonumenTAL-3 trial, talquetamab plus daratumumab (Tal-D), with or without pomalidomide, shows substantial efficacy in the treatment of relapsed/refractory multiple myeloma (RRMM), compared with daratumumab, pomalidomide, and dexamethasone (DPd).